CTLA4 and osteosarcoma: For example, some studies have shown that by inhibiting immunosuppressive pathways such as PD-1/PD-L1 and CTLA-4, the ability of immune cells to attack osteosarcoma cells can be restored, thereby improving the efficacy of immunotherapy (15, 16, 108–110).